Ligand id: 6602

Name: rivastigmine

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: rivastigmine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 32.78
Molecular weight 250.17
XLogP 2.78
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the treatment of Alzheimer's disease [1].
Rivastigmine-induced cholinesterase inhibition may also be beneficial in vascular cognitive impairment (VCI).
A Phase II clinical trial in patients with Parkinson's disease appears to show that rivastigmine (compared to placebo) improves gait dysfunction and decreases the likelihood of falls [2], by ameliorating the underlying cholinergic deficit which contributes to gait and cognitive dysfunction in Parkinson's sufferers. This study is registered with the ISRCTN registry (ID ISRCTN19880883). The study does not address the question of whether the difference between the rivastigmine and placebo groups was due to increased falls in the placebo group as opposed to decreased falls in the rivastigmine group.
Mechanism Of Action and Pharmacodynamic Effects
The exact mechanism of action of rivastigmine is unknown but it appears to bind reversibly to cholinesterase and butyrylcholinesterase. The resultant enzyme inhibition prevents the hydrolysis of acetylcholine which in turn leads to an increase in acetylcholine at cholinergic synapses.
External links